Table 3 The overall sensitivity and specificity (benign vs malignant) of the ADNEX model with and without the inclusion of serum CA125
Cutoff | Patients with risk⩾cutoff, N (%) | Sensitivity with 95% CI | Specificity with 95% CI |
|---|---|---|---|
ADNEX with CA125 | |||
1% | 559 (91.6%) | 100.0% (97.4–100.0) | 11.9% (9.1–15.5) |
3% | 479 (78.5%) | 100.0% (97.4–100.0) | 30.6% (26.3–35.3) |
5% | 383 (62.8%) | 99.0% (94.9–99.8) | 53.2% (48.2–58.1) |
10% | 315 (51.6%) | 97.3% (93.5–98.9) | 67.7% (63.0–72.0) |
15% | 281 (46.1%) | 94.4% (90.0–97.0) | 75.2% (70.7–79.2) |
20% | 253 (41.5%) | 90.6% (85.2–94.1) | 79.3% (75.1–83.0) |
30% | 226 (37.0%) | 86.3% (80.4–90.6) | 83.9% (80.1–87.2) |
ADNEX without CA125 | |||
1% | 557 (91.3%) | 100.0% (97.4–100.0) | 12.4% (9.5–16.0) |
3% | 490 (80.3%) | 100.0% (97.4–100.0) | 28.0% (23.9–32.6) |
5% | 374 (61.3%) | 98.9% (95.7–99.7) | 54.7% (49.9–59.3) |
10% | 317 (52.0%) | 96.7% (92.9–98.5) | 67.1% (62.5–71.3) |
15% | 289 (47.4%) | 94.5% (90.1–97.0) | 72.7% (68.2–76.7) |
20% | 261 (42.8%) | 90.7% (85.5–94.1) | 77.6% (73.4–81.3) |
30% | 225 (36.9%) | 84.6% (78.6–89.2) | 83.4% (80.0–86.6) |
